Newsroom

Senate Committee Examines Drug Pricing Strategies

“For a breakthrough medication to be effective, it needs to be affordable, yet drug makers fail time and time again to abide by this fundamental principle. The Campaign commends the Senate Special Committee on Aging for challenging the pharmaceutical industry on the irresponsible pricing strategies that deliberately deny patients and consumers access to affordable treatments.”

Read more

How Pfizer Set the Cost of Its New Drug at $9,850 a Month

Pfizer’s multistep pricing process shows drugmakers don’t just pick a lofty figure out of the air. At the same time, its process yielded a price that bore little relation to the drug industry’s oft-cited justification for its prices, the cost of research and development. Instead, the price that emerged was largely based on a complex analysis of the need for a new drug with this one’s particular set of benefits and risks, potential competing drugs, the sentiments of cancer doctors and a shrewd assessment of how health plans were likely to treat the product.

Read more

What They Are Saying: Candidates Talk Rx Pricing on the Campaign Trail

Candidates on both sides of the aisle are talking about the harmful impact price tags have on Americans and the facts have been proven time after time: prescription drugs prices are simply out of control.

Read more

Part D Enrollees Who Take Specialty Drugs Will See Out-of-Pocket Costs Rise in 2016

“This latest analysis from the Kaiser Family Foundation paints a troubling picture for the future of the Medicare Part D program and beneficiaries who rely on access to affordable treatments.”

Read more